Investors’ data
Latest news
- December 10, 2008
Thallion Announces a Review of Strategic Alternatives
- November 18, 2008
Thallion Initiates Enrollment in Phase II Metastatic Melanoma Trial
- October 24, 2008
Thallion's TLN-4601 Inhibits Mutated K-RAS Signaling in Cancer Cells
Documentation
Investors Overview
Corporate Office
7150 Alexander-Fleming
Montreal, Quebec
H4S 2C8
Phone: 514-940-3600
Fax: 514-940-3622